Eli Lilly and Company (LLY) Stock Score, Valuation & Financial Research
Eli Lilly and Company is in the Healthcare sector and Drug Manufacturers - General industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 40/100.
Quick answer for LLY
Eli Lilly and Company currently has a Wall Street Score of 40/100. The stored market price is $1K. Its financial score is 24/100. Its valuation score is 4/100. These figures are a research snapshot, not a buy or sell recommendation.
What Eli Lilly and Company does
Eli Lilly and Company is a prominent global pharmaceutical firm dedicated to the research, development, and commercialization of human medicines across the world. Its therapeutic offerings include a comprehensive suite of diabetes medications. This encompasses various insulin formulations like Basaglar, the Humalog family (e.g., Mix 75/25, U-100, U-200, Mix 50/50), insulin lispro products (including protamine and mix 75/25), and the Humulin line (e.g., 70/30, N, R, U-500). Furthermore, Eli Lilly provides specialized treatments for type 2 diabetes, such as Jardiance, Trajenta, and Trulicity. In oncology, Eli Lilly offers a robust portfolio targeting various cancers. These include Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza, indicated for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorect
LLY financial snapshot
- Wall Street Score:
- 40/100
- Current price:
- $1K
- Market capitalization:
- $1.07T
- Revenue:
- $72.25B
- Net income:
- $25.27B
- Free cash flow:
- $8.97B
- Cash:
- $5.14B
- Total debt:
- $43.37B
- EPS:
- 23.00
- P/E ratio:
- 49.5x
- Financial score:
- 24/100
- Valuation score:
- 4/100
- Revenue score:
- 48/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $8.97B, showing positive cash generation.
- The balance sheet shows $5.14B of cash versus $43.37B of total debt, so leverage deserves attention.
What the numbers mean
Its current valuation score is 4/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 24/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research LLY
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.